TTR and hemophilia: In in vivo experiments in mice, AsCas12f-HKRA can target the TTR gene for transthyretin amyloidosis, effectively reduce the expression of TTR, and can also knock in EGFP and coagulation factor F9 genes by HDR to achieve gene therapy for hemophilia mouse models [42].